Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOvoca Bio Regulatory News (OVB)

  • There is currently no data for OVB

Placing

7 Jun 2006 11:24

Ovoca Gold PLC07 June 2006 Ovoca Gold Plc advances following completed Β£5 million Private placement Ovoca Gold Plc (AIM: OVG; IEX: OVX) wishes to announce the successful completionof a private placement to raise Β£5 million. A total of 60,408,452 new OrdinaryShares and 30,204,226 Warrants were placed. The placing consists of one share at8.25p, with one warrant attached to every two shares subscribed for, at a price12p, exercisable by 30 November 2007. The funds raised are to be deployed on the evaluation and development of therecently acquired silver deposit Goltsovoye, located in the Magadan Oblast ofnorth-east Russia, in addition to advancing the company's other projects in theKola Peninsula and in Scandinavia. On 18 April 2006, Ovoca Gold announced that it was acquiring a 74% interest inCJSC Ayax Prospectors Artel Company, the owner of the Goltsovoye licences. Theacquisition consideration is met via the issue of 110,001,518 shares and adeferred payment of US$1 million in cash. The new Russian directors, who joined the Ovoca Gold Board following theapproval of the acquisition of the interest in CJSC Ayax, subscribed Β£2.01million of the Β£5 million private placement. In connection with the placing Ovoca Gold will issue 1.8 million broker warrantsto DBM Capital, at a price of 12 pence exercisable by 30 November 2007. Ovoca Gold Plc is an international exploration company with dual listing in London (OVG.L) and Dublin (OVX.IR), exploring for precious and base metals in Russia, Sweden and Ireland For further information please visit www.ovocagold.com or contact: Dr Barrie Oakes, CEO - Ovoca Gold Plc Roger Turner, Chairman - Ovoca Gold PlcTel: +44 (0)207 397 8151 Tel: +44 (0)207 397 8151Email: barrie.oakes@ovocagold.com Email: roger.turner@ovocagold.com John O'Connor, Secretary - Ovoca Gold Plc Simon Beardsmore, Commercial Manager - Ovoca Gold PlcTel: +353 (0)1 491 2944 Tel: +44 (0)207 397 8151Email john.oconnor@ovocagold.com Email: simon.beardsmore@ovocagold.com John Frain / Fergal Meegan - Davy Richard Chase- Ambrian (AIM Broker)Tel: +353 (0)1 679 6363 +44 (0)207 776 6461Email: john.frain@davy.ie Email: richard.chase@ambrian.com Nick Bias / Alex Buck - Buck Bias (UK PR) Tom McCormack - Connexions PR (Irish PR)Tel: +44 (0)7887 920 530 / +44 (0)7932 740 452 Tel: +353 (0)1 230 3015Email: nick@buckbias.com / alex@buckbias.com Email: tom.mcc@indigo.ie 7 June, 2006 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Jul 20227:00 amRNSCompletion of Enrollment in Phase II Study
30th Jun 20227:00 amRNSAnnual Financial Report
7th Mar 20229:00 amRNSStatement re Russian Business Operations
23rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:36 pmRNSPrice Monitoring Extension
22nd Feb 20223:30 pmRNSRussian Marketing Authorisation for Orenetide
31st Jan 20227:00 amRNSBoard Changes and Update
30th Dec 20217:00 amRNSDirectorate Change
4th Nov 20213:53 pmRNSHolding(s) in Company
4th Nov 20213:50 pmRNSDirector/PDMR Shareholding
4th Nov 20213:46 pmRNSBoard Change
14th Sep 20217:00 amRNSInterim Results
29th Jul 20215:00 pmRNSResult of AGM
24th Jun 20217:00 amRNSAnnual Report and Notice of AGM
10th Mar 20217:00 amRNSMigration of Participating Securities
16th Feb 20212:00 pmRNSResult of EGM
29th Jan 20217:00 amRNSFirst Patient Enrolled in Phase II Study - BP-101
25th Jan 20213:30 pmRNSNotice of EGM
5th Jan 20217:00 amRNSRe-Filing of Marketing Authorisation Application
17th Dec 20202:45 pmRNSResult of AGM
27th Nov 20203:08 pmRNSNotice of AGM
9th Oct 20207:00 amRNSAppointment of Chief Business Officer
2nd Oct 202011:06 amRNSSecond Price Monitoring Extn
2nd Oct 202011:00 amRNSPrice Monitoring Extension
2nd Oct 20209:05 amRNSSecond Price Monitoring Extn
2nd Oct 20209:00 amRNSPrice Monitoring Extension
2nd Oct 20207:00 amRNSUpdate re Russian Marketing Authorisation
28th Sep 20207:00 amRNSDeath of a Director
21st Sep 20207:00 amRNSInterim Results
14th Aug 202011:05 amRNSSecond Price Monitoring Extn
14th Aug 202011:00 amRNSPrice Monitoring Extension
26th Jun 20207:00 amRNSAnnual Report
14th Apr 20202:05 pmRNSSecond Price Monitoring Extn
14th Apr 20202:00 pmRNSPrice Monitoring Extension
24th Mar 20207:00 amRNSAcquisition of Remaining Minority Interest in IVIX
7th Nov 201912:45 pmRNSAttendance at Bio-Europe Conference
16th Sep 20197:00 amRNSInterim Results
12th Sep 20197:00 amRNSFiling of Marketing Authorisation Application
28th Aug 20197:00 amRNSDirectorate Change
8th Aug 20194:14 pmRNSResult of AGM
8th Aug 20199:05 amRNSSecond Price Monitoring Extn
8th Aug 20199:00 amRNSPrice Monitoring Extension
8th Aug 20197:00 amRNSAGM Statement
26th Jul 20197:00 amRNSDirectorate Change
25th Jul 20194:41 pmRNSSecond Price Monitoring Extn
25th Jul 20194:35 pmRNSPrice Monitoring Extension
28th Jun 20197:00 amRNSAnnual Report and Notice of AGM
23rd Apr 20197:00 amRNSUS and EU Clinical Development Plans
29th Mar 20197:00 amRNSDirector/PDMR Shareholding
27th Mar 20197:00 amRNSOperational Update & Additional Investment in IVIX

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.